Peptide Library

FDA-approved

Digestive & weight

Liraglutide

Evidence

FDA approved

Class

GLP-1 receptor agonist

/

Liraglutide

KEY TAKEAWAY

Liraglutide is a modified version of human GLP-1 that lasts about a day in the body. It is sold as Victoza for diabetes and Saxenda for weight management. The FDA approved liraglutide (Victoza) in 2010 for type 2 diabetes and a higher-dose version (Saxenda) in 2014 for weight management. Generic versions are now available.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

GLP-1 receptor agonist

Approved for

Type 2 diabetes and chronic weight management

Key fact

The FDA approved liraglutide (Victoza) in 2010 for type 2 diabetes and a higher-dose version (Saxenda) in 2014 for weight management. Generic versions are now available.

Route

Daily subcutaneous injection

Evidence strength

FDA approved

What it is

What it is

Liraglutide is a modified version of human GLP-1 that lasts about a day in the body. It is sold as Victoza for diabetes and Saxenda for weight management.

How it works

How it works

It activates GLP-1 receptors, which raises insulin release when blood sugar is high, slows stomach emptying and reduces appetite.

Regulatory status

Regulatory status

The FDA approved liraglutide (Victoza) in 2010 for type 2 diabetes and a higher-dose version (Saxenda) in 2014 for weight management. Generic versions are now available.

What it is used for

What it is used for

Type 2 diabetes and chronic weight management.

Side effects and risks

Side effects and risks

Nausea, vomiting and diarrhea are the most common effects. The label carries a boxed warning about thyroid C-cell tumors seen in rodents, and pancreatitis and gallbladder disease are possible.

Citations

Citations

U.S. FDA prescribing information for Liraglutide. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo